Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.
Publication: Journal of Clinical Oncology
Abstract
7502
Background: Treatment options for pts with SCLC that progresses on platinum-based chemotherapy are limited. Pembrolizumab, an anti–PD-1 monoclonal antibody designed to block the interaction between PD-1 and its ligands PD-L1 and PD-L2, has shown antitumor activity in multiple advanced malignancies, including non-small cell lung cancer. We assessed the safety and efficacy of pembrolizumab in pts with PD-L1+SCLC. Methods: KEYNOTE-028 (ClinicalTrials.gov, NCT02054806) is an ongoing multicohort, phase Ib study of pembrolizumab in pts with PD-L1+ advanced solid tumors. Key eligibility criteria for the SCLC cohort include: confirmed, measurable disease; PD-L1 expression in ≥ 1% of cells in tumor nests or PD-L1+ bands in stroma as assessed by IHC at a central laboratory; failure of standard therapy; and absence of autoimmune disease or interstitial lung disease. Pembrolizumab 10 mg/kg is given every 2 wk for up to 2 y or until confirmed progression or unacceptable toxicity. Primary end points are safety, tolerability, and response assessed per RECIST v1.1 by investigator review every 8 wk for the first 6 mo and every 12 wk thereafter. Results: Of the 135 pts with SCLC screened, 37 (27%) had PD-L1+ tumors. Seventeen pts were enrolled from March 2014 through January 2015 (59% men; median age, 62 y; 59% ECOG PS 1). One pt was misenrolled and did not receive pembrolizumab. All 16 treated pts received prior platinum and etoposide. 9 pts (53%) experienced a drug-related AE (DRAE); only 1 pt had a grade ≥ 3 DRAE. There were no treatment-related deaths or discontinuations due to DRAEs. Four of 16 (25%) evaluable pts had a partial response. One (7%) pt had stable disease, resulting in a disease control rate of 31%. Six (37%) pts had progressive disease as their best response, and 5 pts had no assessment at the time of analysis. Responses are durable, with all responders on treatment for 16+ wks with ongoing response. Conclusions: Pembrolizumab is generally well tolerated and has promising antitumor activity in pts with PD-L1+ SCLC who have progressed on prior platinum-based therapy. Enrollment in the SCLC cohort of KEYNOTE-028 is ongoing. Clinical trial information: NCT02054806.
Information & Authors
Information
Published In
Copyright
© 2015 by American Society of Clinical Oncology.
History
Published online: May 20, 2015
Published in print: May 20, 2015
Authors
Metrics & Citations
Metrics
Altmetric
Citations
Article Citation
Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.. JCO 33, 7502-7502(2015).
Download Citation
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Journal of Clinical Oncology 2015 33:15_suppl, 7502-7502
Journal of Clinical Oncology 2015 33:15_suppl, 7502-7502
View Options
View options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to get full access to it.
Subscribe
Subscribe to this Journal
Renew Your Subscription
Become a Member